HeartSciences Announces Closing Of License Agreements With The Icahn School Of Medicine At Mount Sinai To Develop And Commercialize AI Cardiovascular Algorithms
Portfolio Pulse from Benzinga Newsdesk
HeartSciences has closed license agreements with the Icahn School of Medicine at Mount Sinai to develop and commercialize AI-powered ECG algorithms. This partnership makes Icahn Mount Sinai a shareholder in HeartSciences. The company aims to transform cardiovascular disease detection using AI-ECG algorithms, leveraging a cloud-based platform compatible with existing ECG devices. The technology was developed by Icahn Mount Sinai faculty, who have a financial interest in HeartSciences.
November 20, 2023 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HeartSciences has finalized a deal with Icahn School of Medicine to develop AI ECG algorithms, potentially enhancing early heart disease detection and treatment.
The closing of the license agreements with Icahn School of Medicine is a significant step for HeartSciences, as it provides access to advanced AI ECG algorithms and technologies. This partnership is likely to be viewed positively by investors, as it could lead to the development of innovative products that improve early detection of cardiovascular diseases. The news indicates progress in the company's development programs and may lead to increased investor confidence in the company's growth potential.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100